Sanofi SA
SNYNF
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Indexes through a geographic revenue lens.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,925.20 | 11.60 | 0.13% |
| CAC 40 | 8,150.64 | 64.59 | 0.80% |
| DAX 40 | 24,199.50 | 238.91 | 1.00% |
| Dow JONES (US) | 47,951.85 | 65.88 | 0.14% |
| FTSE 100 | 9,837.77 | 63.45 | 0.65% |
| HKSE | 25,667.89 | 169.76 | 0.67% |
| NASDAQ | 23,006.36 | 313.04 | 1.38% |
| Nikkei 225 | 49,668.31 | 666.81 | 1.36% |
| NZX 50 Index | 13,383.61 | 126.84 | 0.96% |
| S&P 500 | 6,774.76 | 53.33 | 0.79% |
| S&P/ASX 200 | 8,632.50 | 11.00 | 0.13% |
| SSE Composite Index | 3,899.31 | 22.94 | 0.59% |